US inappropriate Rxing study "tip of iceberg"

12 December 2001

Over 21% of US seniors, nearly 7 million people, were treated with atleast one of 33 potentially inappropriate medications during 1996, while nearly 3% were given 11 treatments that older people should never receive, reports a study published in the December 12 issue of The Journal of the American Medical Association.

Moreover, lead author Chunliu Zhan of the Agency for Healthcare Research and Quality told Reuters that these findings probably represent only the tip of the iceberg, as they did not look at interactions between drugs and with diseases, drug misuse or underuse. Other patient groups at risk include women, those in poor health and people taking the highest number of medicines, said the study, warning that the problem could worsen with the proposed Medicare prescription drug benefit.

Reasons for the problem include the fact that seniors are not usually included in clinical trials, particularly those suffering from more than one condition, said Dr Zhan. Also, their physicians may not have geriatric care training, and patients themselves may demand particular products which they have found worked before.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight